RESTARI advances innovative device and pharmaceutical products. We emphasize acute kidney injury, polycystic kidney disease, and adjacent biopsy technologies. 

Acute Kidney Injury

Acute kidney injury (AKI) occurs when low blood pressure causes blood cells to aggregate in renal capillaries and reduce blood flow. This reduction triggers inflammation, impedes nutrient supply and impairs filtration by the kidney.
AKI can cause permanent kidney damage leading to dialysis, chronic kidney disease and even death. Currently, there are no therapies for AKI. RESTARI is in late-stage clinical development of the first device to stop and reverse AKI when it first occurs.

Polycystic Kidney Disease

Polycystic Kidney Disease (PKD) is a genetic disease that causes progressive kidney damage. RESTARI is working to develop a well-tolerated, once daily tablet intended to shrink cyst size and slow their growth. RESTARI is in the discovery phase of a gene therapy treatment meant to repair the mutation that causes PKD.

Biopsy

RESTARI's emerging biopsy device portfolio uses patented technology to capture large specimens to aide diagnoses. Making sure physicians are able to have more of the necessary material to work with.